Gastrointestinal (GI): NSAIDs that block COX-1 activity have correlations with GI issues due to inhibition with the synthesis of gastroprotective agents like PGE2 and various prostaglandins. This inhibition contributes to lessened mucin manufacturing by gastric epithelial cells, a lot less bicarbonate secretion, and fewer epithelial mobile turnover, among the other https://thomasm175rua3.webdesign96.com/profile